Clarametyx Biosciences has received approval from the Independent DMC to progress its Phase Ib/IIa trial of CMTX-101 ...

The US FDA has approved Ocugen’s IND amendment to commence a Phase II/III pivotal confirmatory study of OCU410ST.

This space already includes two approved CAR T-cell therapies: Johnson & Johnson/Legend’s Carvykti and Bristol Myers Squibb’s ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Astria Therapeutics has reported encouraging initial outcomes from its ongoing ALPHA-SOLAR trial of navenibart for HAE ...

At EHA 2025, the preliminary results from the global, multi-centre open-label non-randomised Phase II RedirecTT-1 clinical ...

Johnson & Johnson (J&J) has reported new outcomes from the Phase II RedirecTT-1 trial of bispecific antibodies, Talvey and ...

Genmab has reported new outcomes from the Phase Ib/II EPCORE NHL-2 trial Arm 10 of T-cell engaging bispecific antibody, ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582.

MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

HepaRegeniX has begun dosing subjects in a Phase Ib trial of HRX-215 in subjects undergoing partial liver resection due to ...